Post Surgical Pain Clinical Trials

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Newland Medical Associates-Pontiac

from

Pontiac, MI

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Mercy Regional Cancer Center

from

Redding, CA

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Saint Charles Health System-Redmond

from

Redmond, OR

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Neurosurgeons of New Jersey-Ridgewood

from

Ridgewood, NJ

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Delbert Day Cancer Institute at PCRMC

from

Rolla, MO

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Siteman Cancer Center at Saint Peters Hospital

from

Saint Peters, MO

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

City of Hope - Santa Clarita

from

Santa Clarita, CA

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Summit Cancer Care-Candler

from

Savannah, GA

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Regional West Medical Center Cancer Center

from

Scottsbluff, NE

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Geisinger Medical Oncology-Selinsgrove

from

Selinsgrove, PA

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Maine Medical Partners - South Portland

from

South Portland, ME

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Baptist Memorial Hospital and Cancer Center-Desoto

from

Southhaven, MS

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Rockwood North Cancer Treatment Center

from

Spokane, WA

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Bhadresh Nayak MD PC-Sterling Heights

from

Sterling Heights, MI

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Promedica Flower Hospital

from

Sylvania, OH

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

SUNY Upstate Medical Center-Community Campus

from

Syracuse, NY

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Ascension Saint Joseph Hospital

from

Tawas City, MI

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Sanford Thief River Falls Medical Center

from

Thief River Falls, MN

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Cotton O'Neil Cancer Center / Stormont Vail Health

from

Topeka, KS

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Gene Upshaw Memorial Tahoe Forest Cancer Center

from

Truckee, CA

Great Lakes Cancer Management Specialists-Macomb Professional Building

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Warren, MI

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

City of Hope West Covina

from

West Covina, CA

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Woodland Memorial Hospital

from

Woodland, CA

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

Wright-Patterson Medical Center

from

Wright-Patterson Air Force Base, OH

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Pali Momi Medical Center

from

'Aiea, HI

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

The Cancer Center of Hawaii-Pali Momi

from

'Aiea, HI

University of Iowa Healthcare Cancer Services Quad Cities

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Bettendorf, IA

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Aurora Cancer Care-Southern Lakes VLCC

from

Burlington, WI

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

University of Cincinnati/Barrett Cancer Center

from

Cincinnati, OH

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

AdventHealth Infusion Center Haywood

from

Clyde, NC

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Walter Knox Memorial Hospital

from

Emmett, ID

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Hawaii Cancer Care Inc-Liliha

from

Honolulu, HI

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

OptumCare Cancer Care at Fort Apache

from

Las Vegas, NV

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

ProHealth D N Greenwald Center

from

Mukwonago, WI

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

Lakeland Hospital Niles

from

Niles, MI

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Status: Enrolling, Phase II
Updated: 12/31/1969

ProHealth Oconomowoc Memorial Hospital

from

Oconomowoc, WI

Bladder Cancer Clinical Trial

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Status: Enrolling, Phase II
Updated: 12/31/1969

IHA Hematology Oncology Consultants-Ann Arbor

from

Ypsilanti, MI

Bladder Cancer Clinical Trial

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Status: Enrolling, Phase II
Updated: 12/31/1969

Yuma Cancer Center

from

Yuma, AZ

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Status: Enrolling, Phase II
Updated: 12/31/1969

Cleveland Clinic Akron General

from

Akron, OH

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Sloan Kettering Commack

from

Commack, NY

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Status: Enrolling, Phase II
Updated: 12/31/1969

Northwestern Medicine Cancer Center Kishwaukee

from

DeKalb, IL

University of Florida Health Science Center ?? Gainesville

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Gainesville, FL

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Status: Enrolling, Phase II
Updated: 12/31/1969

Wellspan Health - York Cancer Center

from

York, PA

Syncope Clinical Trial

Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

from

Cincinnati, OH

Syncope Clinical Trial

Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

from

Jacksonville, FL

Syncope Clinical Trial

Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study

Status: Enrolling
Updated: 12/31/1969

Clinical Research Facility

from

Minneapolis, MN

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Status: Enrolling, Phase III
Updated: 12/31/1969

ThedaCare Regional Cancer Center

from

Appleton, WI

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Status: Enrolling, Phase IV
Updated: 12/31/1969

Children's Hospital of Michigan - Hematology Clinic

from

Detroit, MI

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Status: Enrolling, Phase IV
Updated: 12/31/1969

JDCH Division of Pediatric Hematology and Oncology

from

Hollywood, FL

The Children's Hospital of Philadelphia - Investigational Pharmacy

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Status: Enrolling, Phase IV
Updated: 12/31/1969

from

Philadelphia, PA

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Status: Enrolling, Phase IV
Updated: 12/31/1969

Kaiser Permanente Roseville Medical Center

from

Roseville, CA

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Status: Enrolling, Phase IV
Updated: 12/31/1969

UCSF Mission Bay Pediatric Clinical Research Center

from

San Francisco, CA

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Status: Enrolling, Phase IV
Updated: 12/31/1969

Prince of Wales Hospital

from

Sydney,

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Anchorage Associates in Radiation Medicine

from

Anchorage, AK

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

PCR Oncology

from

Arroyo Grande, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

AIS Cancer Center at San Joaquin Community Hospital

from

Bakersfield, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Medical Center of Baton Rouge

from

Baton Rouge, LA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Nebraska Medicine-Bellevue

from

Bellevue, NE

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

West Virginia University Charleston Division

from

Charleston, WV

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

University Oncology Associates

from

Clovis, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Coffeyville Regional Medical Center

from

Coffeyville, KS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

City of Hope Corona

from

Corona, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Siteman Cancer Center at West County Hospital

from

Creve Coeur, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Miami Valley Hospital North

from

Dayton, OH

Great Lakes Cancer Management Specialists-Doctors Park

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

East China Township, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

IMG Hematology Oncology 8505

from

Fairfax, VA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Sanford Broadway Medical Center

from

Fargo, ND

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Sanford South University Medical Center

from

Fargo, ND

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Essentia Health - Fosston

from

Fosston, MN

Wheaton Franciscan Healthcare-Saint Francis/Reiman Cancer Center

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Franklin, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Grand Valley Oncology

from

Grand Junction, CO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Baptist Cancer Center-Grenada

from

Grenada, MS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Sloan Kettering Westchester

from

Harrison, NY

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

AdventHealth Hendersonville

from

Hendersonville, NC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ann M Wierman MD LTD

from

Las Vegas, NV

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

PeaceHealth Saint John Medical Center

from

Longview, WA

Saint Mary's Oncology/Hematology Associates of Marlette

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Marlette, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

WVUH-Berkely Medical Center

from

Martinsburg, WV

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Sovah Health Martinsville

from

Martinsville, VA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Marjorie Weinberg Cancer Center at Loyola-Gottlieb

from

Melrose Park, IL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Alphonsus Medical Center-Nampa

from

Nampa, ID

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

New York, NY

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Vincent Hospital Cancer Center at Oconto Falls

from

Oconto Falls, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Baptist Memorial Hospital and Cancer Center-Oxford

from

Oxford, MS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mercy Health Perrysburg Cancer Center

from

Perrysburg, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Hope Cancer Center

from

Pontiac, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

21st Century Oncology-Pontiac

from

Pontiac, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

City of Hope Rancho Cucamonga

from

Rancho Cucamonga, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente Downtown Commons

from

Sacramento, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ascension Saint Mary's Hospital

from

Saginaw, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Lakeland Medical Center Saint Joseph

from

Saint Joseph, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Smilow Cancer Hospital-Torrington Care Center

from

Torrington, CT

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

ProHealth Waukesha Memorial Hospital

from

Waukesha, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

WellSpan Health-York Hospital

from

York, PA